Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Auro LaboratoriesBOM:530233 +1.16%57 Days Payable is 209.40 as of Mar. 2026, which is 191% above its 10-year median of 71.92. GuruFocus rates BOM:530233 with a GF Score™ of 57/100 and a GF Value™ of ₹152.37 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 926 Drug Manufacturers companies, Auro Laboratories ranks better than 94.38% on this metric.
The historical rank and industry rank for Auro Laboratories's Days Payable or its related term are showing as below:
BOM:530233'
s Days Payable Range Over the Past 10 Years
Min: 57.67 Med: 71.92 Max: 478.38
Current: 478.38
During the past 13 years, Auro Laboratories's highest Days Payable was 478.38. The lowest was 57.67. And the median was 71.92.
BOM:530233's Days Payable is ranked better than 94.38% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs BOM:530233: 478.38
Auro Laboratories's Days Payable
increased
from Mar. 2025 (110.40) to Mar. 2026 (209.40).
It may suggest that Auro Laboratoriesdelayed paying its suppliers.
The historical data trend for Auro Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Auro Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Auro Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Auro Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Auro Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Auro Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Auro Laboratories (BOM:530233) has a Days Payable of 209.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Auro Laboratories and its competitors. This is 191% above median its historical median of 71.92. Over the past decade, Auro Laboratories' Days Payable has ranged from 57.67 to 478.38. According to the industry distribution chart, Auro Laboratories ranks #52 out of 926 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Auro Laboratories' Days Payable too high?
Auro Laboratories' current Days Payable of 209.40 is 191% above median its 10-year median of 71.92. Over the past 10 years, this metric has ranged from a low of 57.67 to a high of 478.38. The Drug Manufacturers industry median Days Payable is 90.22. Auro Laboratories' value of 209.40 is 132.1% above this industry median. Based on the distribution chart, Auro Laboratories ranks #52 out of 926 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Auro Laboratories has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Auro Laboratories' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Auro Laboratories ranks #52 out of 926 companies for Days Payable. This places Auro Laboratories in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.22. Auro Laboratories' value of 209.40 is 132.1% above this benchmark. Historically, Auro Laboratories' own Days Payable has ranged from 57.67 to 478.38 over the past decade. While the company's 10-year median is 71.92 vs. the industry median of 90.22, Auro Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Auro Laboratories's current Days Payable of 209.40 is 132.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Auro Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Auro Laboratories's current Days Payable is 209.40, which is 191% above median its own 10-year median of 71.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Auro Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Auro Laboratories (BOM:530233) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹152.37, compared to a current price of ₹234.75 — trading 54.1% above its estimated fair value. The current Days Payable is 209.40, which is 191% above median its 10-year median of 71.92 and 132.1% above the Drug Manufacturers industry median of 90.22. Auro Laboratories' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Auro Laboratories (BOM:530233), the current Days Payable is 209.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Auro Laboratories (BOM:530233) Overvalued in 2026?
Based on GuruFocus' analysis, Auro Laboratories stock appears to be overvalued.
The current stock price of ₹234.75 is trading 54.1% above its estimated GF Value™ of ₹152.37.
GuruFocus considers Auro Laboratories to be Significantly Overvalued.
Key valuation signals for BOM:530233:
Days Payable: 209.40 (191% above median its 10-year median of 71.92)
GF Value™: ₹152.37 vs. price of ₹234.75 (54.1% above fair value)
Industry Position: 132.1% above the Drug Manufacturers median (#52 of 926)
No single metric tells the full story. See the BOM:530233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Auro Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and selling of pharmaceutical products like Metformin Hydrochloride and Glibenclamide. The pharmaceutical products range offered by the company are anti-diabetic, muscle relaxant, diuretic, iron deficiency anti-fungal, anti-ulcer, iodine supplement, anti-malaria, antacids, anti-inflammatory, specialty chemicals, and others. The company sells its products in India and also exports it to international countries.
57GF Score
Get the complete analysis for BOM:530233
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530233 has been successfully added to your 
